Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 12

Results For "EUROPE"

1151 News Found

Zydus wellness reports 31% growth in net sales in Q2 FY26
News | November 06, 2025

Zydus wellness reports 31% growth in net sales in Q2 FY26

During the quarter, Zydus Wellness completed the acquisition of Comfort Click Limited and its subsidiaries


J&J MedTech reports strong one-year results for shockwave peripheral IVL system in DISRUPT BTK II trial
News | November 06, 2025

J&J MedTech reports strong one-year results for shockwave peripheral IVL system in DISRUPT BTK II trial

The study demonstrated strong clinical outcomes, with 94.8 per cent of subjects remaining free from major target limb amputation at one year


Teva reports 11th consecutive quarter of growth
News | November 06, 2025

Teva reports 11th consecutive quarter of growth

Teva reported third quarter revenues of $4.5 billion, an increase of 3 per cent year-over-year.


Roche’s Gazyva shows breakthrough efficacy in phase III lupus study
Clinical Trials | November 04, 2025

Roche’s Gazyva shows breakthrough efficacy in phase III lupus study

The ALLEGORY study demonstrated statistically significant improvements in key measures, including British Isles Lupus Assessment Group-based Composite Lupus Assessment (BICLA) response


Lilly to build $3 billion oral medicine facility in Netherlands
News | November 04, 2025

Lilly to build $3 billion oral medicine facility in Netherlands

Netherlands site will bring 500 manufacturing and 1,500 construction jobs while further strengthening Lilly's global supply chain


Gland Pharma reports Q2 FY26 PAT higher at Rs. 184 Cr
News | November 04, 2025

Gland Pharma reports Q2 FY26 PAT higher at Rs. 184 Cr

Revenue for the quarter rose 5.8% to Rs. 1,487 crore as compared to Rs. 1,406 crore in the corresponding quarter of the previous fiscal


EU approves Alexion’s Koselugo to treat adults with neurofibromatosis type 1 tumours
Clinical Trials | October 31, 2025

EU approves Alexion’s Koselugo to treat adults with neurofibromatosis type 1 tumours

Approval based on pivotal KOMET Phase III trial demonstrating significant tumour reduction in adults with NF1


Roche’s Gazyva shows strong phase III results for treatment of idiopathic nephrotic syndrome
Clinical Trials | October 30, 2025

Roche’s Gazyva shows strong phase III results for treatment of idiopathic nephrotic syndrome

Key secondary endpoints also demonstrated statistically significant and clinically meaningful benefits with Gazyva


BMS unveils new data highlighting sustained efficacy and safety of Sotyktu in psoriatic arthritis and lupus
Clinical Trials | October 30, 2025

BMS unveils new data highlighting sustained efficacy and safety of Sotyktu in psoriatic arthritis and lupus

Sotyktu continues to demonstrate consistent efficacy and safety across rheumatic conditions


AskBio’s gene therapy shows promising 12-month results for heart failure
Biotech | October 29, 2025

AskBio’s gene therapy shows promising 12-month results for heart failure

Results demonstrate favorable safety profile and clinically meaningful improvements in patients with non-ischemic heart failure